Prostate Cancer Clinical Trial: ARN-509

Formerly certified by Japan's Ministry of Foreign Affairs and METI as an international medical visa guarantor (B-066).

Prostate Cancer Clinical Trial: ARN-509

• March 1, 2015
• 2 min read

A Phase III clinical trial is underway using ARN-509, a second-generation anti-androgen agent, for patients with previously untreated prostate cancer. This study specifically targets high-risk patients with non-metastatic prostate cancer who have a rapidly increasing PSA level (PSA doubling time of 10 months or less). The trial evaluates the efficacy and safety of the drug compared to a placebo.

Eligibility Criteria:

1. Patients aged 18 years or older.
2. Confirmed diagnosis of prostate cancer.
3. High risk of metastasis (PSA doubling time ≤ 10 months).
4. PSA levels continuing to rise (> 2 ng/mL) despite androgen deprivation therapy (ADT).

For more details, visit: Clinical Trials JP

Drug Description: Androgen Receptor Antagonist ARN-509

A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. Ultimately, this inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.

Trial Period: March 1, 2015 – December 31, 2016

#ProstateCancer #ClinicalTrial #ARN509 #Apalutamide #AntiAndrogen #CancerResearch

Figure 1

Figure 2

Figure 3

Figure 4